Two Biotechs Just Rang the IPO Bell on the Same Day

The Phase 2 data looks genuinely impressive. Patients on the weekly dosing schedule saw an estimated 87% reduction in treated bleeding episodes. That's not incremental; that's transformative for people who currently have very few options. The FDA apparently agreed: in March 2026, it granted sutacimig Breakthrough Therapy Designation. It had previously received Fast Track and Orphan Drug status. A pivotal Phase 3 trial is planned for this year.

Hemab also has a second program, HMB-002, in early testing for Von Willebrand disease, and an ambitious roadmap they call "Hemab 2x3 by 2030" (two commercial drugs, two late-stage, two early-stage programs). The joint bookrunners on the deal are Goldman Sachs, Jefferies, and Evercore ISI.

The IPO Drought Is (Probably) Over

If you zoom out, these filings are part of a larger pattern. After biotech IPOs basically flatlined in 2025, Q1 2026 quietly turned into a strong opening quarter. Volume was still modest, but the deals were big: total Q1 proceeds hit $1.7 billion, with a median raise of $287.5 million per IPO, more than double the Q1 2025 figure.

The headline act came in mid-April, when Kailera Therapeutics (an obesity drug developer) raised a staggering $625 million in what's believed to be the largest biotech IPO in Nasdaq history. Its shares popped 62.5% on day one. The very next day, Alamar Biosciences priced at the top of its range and jumped 33%.

Analysts are projecting 20 to 35 biotech IPOs for the full year. One industry forecaster said that if his estimate of 30 to 35 was wrong, he was probably being "too conservative."

Not Everyone Gets a Ticket to the Party

Before you start imagining a repeat of 2021's bonanza (99 biotech IPOs that year, fueled by COVID-era enthusiasm), the reality is more selective. Investors aren't throwing money at anything with a lab coat and a PowerPoint. The companies getting through the window share a few common traits: mid- to late-stage clinical data, prior large venture funding, and a focus on hot therapeutic areas.

Platform companies without clinical proof are finding it tougher. The message from Wall Street is clear: show us the data, keep your spending lean, and we'll talk.

Seaport's potential valuation of up to $912 million and Hemab's at roughly $706 million (fully diluted) suggest investors are willing to pay up for the right stories. Both companies are pre-revenue, which is standard for clinical-stage biotechs, but the bar for "what counts as a good story" has gone way up since the easy-money days.

Why This Matters Beyond Wall Street

IPOs aren't just financial events. They're funding mechanisms for drugs that could change (or save) lives. When the IPO window slams shut, promising science gets stuck in development limbo. Companies delay trials, cut programs, or die altogether.

A reopening window means more shots on goal. Seaport's depression drug could become a new option for millions of people who don't respond well to existing antidepressants. Hemab's sutacimig could be the first real prophylactic treatment for Glanzmann thrombasthenia, a condition so rare that most people have never heard of it, yet devastating for those who have it.

Seaport is expected to price on April 30 under the ticker SPTX. Hemab will trade as COAG on Nasdaq (a fitting ticker for a clotting company, if there ever was one).

Two very different companies. Two very similar bets that the biotech IPO market is ready to thaw. If they're right, expect a lot more S-1 filings in your news feed this summer.